Kornimate/medical-research-clean huggingface dataset:
rapid assessment of bedside bnp in treatment of heart failure (rabbit)

Conditions: Heart Failure

Summary: to determine the clinical utility of using the triage® bnp test to guide therapy in outpatients with heart failure

the triage® bnp test has been cleared by the u.s. food and drug administration as an aid in the diagnosis and assessment of severity of heart failure. in addition to numerous reports describing the diagnostic and prognostic utility of bnp, reports from various pilot studies have described decreases in bnp in association with various heart failure therapies. other reports have described modest increases in bnp in association with digitalis and beta-receptor antagonism. the observation that the circulating bnp concentration decreases during heart failure therapy, coupled with the ability of bnp to be used as a prognostic tool and assess the severity of heart failure, it is hypothesized that using bnp measurements to guide heart failure therapy could have a significant impact on the care of heart failure patients. this hypothesis is supported by various reports of pilot studies that describe a significant benefit of administering therapy tailored to concentrations of bnp and related peptides. patients that are discharged after a hospitalization for heart failure will be approached for study enrollment.this is a multi-center, single (patient)-blinded cluster-randomized study. half of the sites will have bnp measurements available to guide therapy (experimental arm) and the other half of the sites will not have bnp measurements available (control arm). blood (plasma) will be collected at each visit and appropriate forms completed. patients will be asked to complete a minnesota living with heart failure questionnaire and to do a 6-minute walk test. patients will be followed for 12 months.

Eligibility criteria:
inclusion criteria: age 18 or older patient was hospitalized and treated for heart failure patient is fully stabilized at discharge able to give informed consent exclusion criteria: history of severe pulmonary disease chronic o2 therapy for copd primary pulmonary hypertension history of renal disease requiring dialysis history of severe hepatic disease patients using lvad's stroke, mi, ptca, cabg or unstable angina within the past 1 month bi-ventricular pacemaker placement within last 1 month history of severe aortic stenosis history of severe mitral stenosis history of constrictive pericarditis patient has had a cardiac transplant status 1 cardiac transplant candidates icd or drg assignment of non-q wave mi within last 1 month patient has cor pulmonale a re-hospitalization, death or an iv treatment for heart failure before the first post-discharge visit and/or15) planned chronic iv treatment.
rtms and multi-modality aphasia therapy for post-stroke aphasia

Conditions: Stroke; Aphasia, Non-fluent

Summary: many stroke survivors experience aphasia, a loss or impairment of language affecting the production or understanding of speech. one common type of aphasia is known as non-fluent aphasia. patients with non-fluent aphasia have difficulty formulating grammatical sentences, often producing short word fragments despite having a good understanding of what others are trying to communicate to them. speech language pathologists (slps) play a central role rehabilitating persons with aphasia and administer therapy in an attempt to improve communication skills. despite standard therapy, approximately 50% of individuals who experience aphasia acutely continue to have language deficits more than 6 months post-stroke. in most people, broca's area is dominant in the left side of the brain. following a left-sided stroke, the right-sided homologue of broca's area (the pars triangularis), may adopt language function. unfortunately, reorganizing language to the right side of the brain seems to be less effective than restoring function to the left hemisphere. repetitive transcranial magnetic stimulation (rtms), a form of non-invasive brain stimulation, can be used to suppress activity of specific regions in the right side of the brain to promote recovery of function in the perilesional area. despite preliminary success in existing studies using rtms in post-stroke aphasia, there is much work to be done to better understand the mechanisms underlying recovery. responses to rtms have been positive, yet heterogenous, which may be related to timing of treatments following stroke.


Eligibility criteria:
inclusion criteria: * isolated left middle cerebral artery (mca) stroke more than 6 months ago (chronic) * stroke type: ischemic or hemorrhagic * non-fluent aphasia as determined by the western aphasia battery (fluency \< 5) * right-hand dominant prior to stroke * english is first or primary language * ability to follow 3-step commands exclusion criteria: * prior stroke to the right frontal lobe * current diagnosis of moderate to severe depression * diagnosis of any other psychiatric condition * history of other neurologic disorders (e.g., epilepsy, brain tumor) * contraindication to mri or tms (metal in the head or any implanted electrical device) * has received intensive speech therapy within the past 6 months (\>8 hours per week) * enrolled in another interventional study

Keywords: non-invasive brain stimulation transcranial magnetic stimulation multi-modality aphasia therapy neuroimaging stroke aphasia aphasia, broca speech disorders language disorders
can protein intake be increased by offering protein-enriched foods and drinks?

Conditions: Undernutrition

Summary: the objective of this study is to investigate whether a protein-enriched daily menu is acceptable and effective in increasing protein intake in elderly in a residential care home up to an intake of 1,2 gram/ kg body weight per day. the investigators hypothesise that when elderly eat 2 slices of bread, 1 portion of juice and 1 portion of soup each day, the protein intake can be increased by at least 20 grams/day. on average this can lead to an intake of 1,2 gram/ kg body weight per day.

rationale: due to inactivity, elderly are prone to lose muscle mass. with an increased protein intake, muscle mass might be maintained. the current recommendation for protein intake for elderly is the same as for younger adults, but researchers and geriatricians appeal for a higher recommended protein intake to maintain health and function. one way to reach a higher intake is by providing protein-enriched foods. because of concerns that these foods are more satiating, careful monitoring of protein intake after introducing these foods is warranted. objective: to investigate whether a protein-enriched daily menu is acceptable and effective in increasing protein intake in elderly in a residential care home up to an intake of 1,2 gram/ kg body weight per day. study design: dietary intake will be monitored before and after introducing a protein-enriched daily menu. the menu will be provided for 10 days to all residents of the care home. for residents who give consent, intake will be recorded by trained research assistants and nurses on 2 consecutive days before the pilot and on days 9 and 10 of the pilot. after the pilot residents will return to their regular menus. study population: the study population consists of elderly men and women (aged 65 or older) living in a care home in wageningen, the netherlands. intervention: a protein-enriched daily menu for 10 days. main study parameters/endpoints: protein intake and resident satisfaction with the menu.

Eligibility criteria:
inclusion criteria: * aged 65 or older * living in care home nudehof * able to give consent * without dietary protein restrictions exclusion criteria: * cognitive impaired * having dementia * having dysphagia * receiving only tube feeding * known kidney disease * having food allergies that exclude them from having the protein-enriched products * following a low protein diet or a diet low in sodium * receiving palliative care

Keywords: elderly protein enrichment undernutrition
assessing endoloop-assisted polypectomy in patients with antiplatelet therapy

Conditions: Colorectal Polyp

Summary: the aims of this study were to examine: 1) safety and feasibility of antiplatelet therapy interruption 7 days prior to polypectomy in patients with long-term antiplatelet therapy; 2) safety and feasibility of endoloop assisted snare polypectomy in patients with long-term antiplatelet therapy; 3) safety and feasibility of so called "ligate and let go" approach in patients with long-term antiplatelet therapy.


Eligibility criteria:
inclusion criteria: * pedunculated colorectal polyps * larger than 2cm in diameter * long-term antiplatelet therapy exclusion criteria: * presence of intraepithelial
the effect of mechanical vibration and shotblocker on pain levels during heel lance in healthy term neonates

Conditions: Procedural Pain

Summary: this study was conducted to determine the effect of mechanical vibration and shotblocker methods on pain level, crying time and procedure time during heel prick blood collection in healthy term infants.

heel prick blood collection, which is one of the painful medical procedures, is one of the diagnostic methods used in newborns and is a more painful procedure compared to other blood collection procedures. prevention of pain in newborns should be the primary goal of all healthcare personnel working with newborns, both because it is an ethical obligation and because repeated painful exposures have the potential to cause harmful consequences. nonpharmacologic methods used for the control of acute pain associated with medical procedures are easy to use, have no side effects, are inexpensive and time-saving. mechanical vibration and shotblocker application are among the non-pharmacologic methods frequently used in the management of pain associated with heel prick procedure in term infants. previous studies have shown that parent-related methods (kangaroo care, mother/father hug, breastfeeding, etc.) are commonly used for pain management of the newborn during heel prick. in this respect, it is important to determine the effectiveness of mechanical vibration and shotblocker methods that can be used independently of the parent, especially in intensive care settings where access to the parent is not always possible.

Eligibility criteria:
inclusion criteria: * with a postnatal age of 24-72 hours, * birth weight of 2500 g and above, * 5th minute apgar score above 6, * able to carry out vital activities without support, * fed within one hour before the procedure, * calm and not crying before the procedure, * babies who had heel prick for the first time exclusion criteria: * with genetic or congenital anomaly, * with neurological, cardiological and metabolic diseases, * in need of respiratory support, * having a history of sedative, analgesic, or narcotic use within 24 h before admission, * hospitalization and surgical procedure experience in neonatal intensive care unit, * experience with needle interventions other than vitamin k and hepatitis b vaccine, * babies of mothers with a history of substance abuse

Keywords: procedural pain term neonate nonpharmacological pain management
even - effects of vr on empathy for nature in patients with psychosis and depressive disorders

Conditions: Depressive Disorder; Schizophrenia; Healthy Control

Summary: study group: experimental study to evaluate empathy, compassion, and nature connectedness before and after an immersive virtual reality experience in patients with depressive disorder, patients with psychotic disorder and healthy control subjects (subjects between 18 and 65 years of age). primary hypothesis: the increase in nature connectedness explored by virtual body ownership of a tree in vr differs depending on the health condition (schizophrenia, depression, healthy controls).


Eligibility criteria:
inclusion criteria: * age: 18-65 years * inpatients and outpatients treated at the psychiatric university clinic of the charité at st. hedwig hospital * diagnosis of depressive disorder (icd-10: f32.x, f33.x) or diagnosis of schizophrenia (f20.x) or healthy controls without psychiatric diagnosis * able to provide written informed consent exclusion criteria: * acute suicidality or danger to others * primarily treatment-requiring eating disorder * acute dermatological condition affecting the hands that can distort skin conductivity measurements * control group: psychiatric or psychosomatic pre-diagnoses (except for the psychiatric active control group), other exclusion diagnoses corresponding to the patient group
postpartum depression

Conditions: Postpartum Depression; Melatonin

Summary: our aim was to diagnose and initiate early treatment for postpartum depression by detecting the changes of melatonin levels in c-sections with different antesthesia modalities.


Eligibility criteria:
inclusion criteria: * pregnant women c-section (using general or regional anesthesia) aged between 18-45 years exclusion criteria: * age under 18 or above 45, history of smoking, a diagnosis with mental retardation, psychiatric patients, use of antipsychotics or antidepressants, patients with sleeping disorders, hormone replacement theraphy patients.
assessment of quality of life in patients with symptomatic chemotherapy-induced anaemia

Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors; Bladder Cancer; Endometrial Cancer; Renal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer

Summary: this is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric) and who are receiving darbepoetin alfa (aranesp®) or other erythropoiesis-stimulating agent (esa) to treat symptomatic anaemia. quality of life will be assessed electronically with the aim of estimating improvement in quality of life for those patients receiving darbepoetin alfa (aranesp®) who also have an increase in haemoglobin (hb) of ≥1 g/dl

before enrolling participants, each country was assigned to either cohort 1 (patients receiving only darbepoetin alfa) or cohort 2 (patients receiving any esa). cohort 2 was assigned only to those countries in which local regulations did not permit observational study participation by patients receiving a specific agent in a drug class.

Eligibility criteria:
inclusion criteria: * diagnosed with breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric cancer * expected to receive at least 8 additional weeks of a given regimen of myelosuppressive chemotherapy after enrolment * starting treatment with either darbepoetin alfa (in cohort 1 countries) or any esa (in cohort 2 countries) as per european summary of product characteristics (spc) for symptomatic anaemia. exclusion criteria: * received any esa treatment or red blood cell (rbc) transfusion within 28 days prior to enrolment * known primary benign or malignant haematologic disorder which can cause anaemia * known hypersensitivity to esas

Keywords: breast cancer lung cancer ovarian cancer prostate cancer colorectal cancer aranesp chemotherapy induced anaemia chemotherapy bladder cancer endometrial cancer renal cancer pancreatic cancer esophageal cancer gastric cancer
neurodevelopmental assessment of infants with cystic fibrosis

Conditions: Neurodevelopmental Disorders; Cystic Fibrosis

Summary: infants included in the study will be divided into two groups as healthy infants and cystic fibrosis infants . demographic, natal and postnatal information of the infants will be available from patient files. 12 months infants with cystic fibrosis and healthy infants will be assessed by the bayley-iii baby and child development assessment scale (bayley iii) and the gross motor function measure. the assessment outcomes of healthy and cystic fibrosis infants will be compared.


Eligibility criteria:
inclusion criteria: * having diagnosis of cystic fibrosis * to be postterm24-36 months old exclusion criteria: * having congenital anomalies, * having an acute infection, * risk of high or low neurological impairment due to perinatal stroke, perinatal asphyxia, intra / peri-ventricular hemorrhage (ivh / pvl), bronchopulmonary dysplasia, * the baby's family not reluctant to involved in study.

Keywords: cystic fibrosis neurodevelopment early rehabilitation
stroke thrombectomy and aneurysm registry

Conditions: Stroke; Thromboses, Intracranial; Aneurysm, Brain

Summary: this international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. this information is used to help predict outcomes that undergo an operation for treatment of the above-listed brain injuries. additionally, the information is used to compare techniques and devices' effects on technical and clinical outcomes.


Eligibility criteria:
inclusion criteria: * undergoing surgical intervention for central nervous system vascular lesion * between 1 and 120 years of age exclusion criteria: * no exclusion criteria
evaluation of extended infusion set wear using medtronic extended wear sof-set infusion set

Conditions: Type 1 Diabetes

Summary: this is a blinded cross-over study to see if extended wear insulin infusion sets can prolong insulin infusion set wear up to 7 days in adults with type 1 diabetes.

this is a double blinded cross-over study. subjects will be asked to wear infusion set either a standard infusion set or an extended wear infusion set. they will wear each infusion set twice, and the order of infusion set wear will be randomized with the first infusion set wear and then alternated over 4 weeks. by performing a cross over study using both experimental infusion sets and standard infusion sets, the investigators hope to see whether there is a benefit to using an extended wear infusion set.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 12 months 2. the diagnosis of type 1 diabetes is based on the investigator's judgment; c-peptide level and antibody determinations are not needed. 3. age 18 to 55 years 4. hemoglobin a1c level less than or equal to 8.5% 5. willing to use novolog insulin while they are participating in the study 6. total daily insulin dose is at least 0.3 units/kg/day 7. for females, not currently known to be pregnant 8. an understanding of and willingness to follow the protocol and sign the informed consent 9. willingness to wear the experimental insulin infusion sets throughout the study 10. must be able to understand spoken and written english exclusion criteria: 1. diabetic ketoacidosis in the past 3 months 2. blood urea nitrogen (bun), creatinine, or liver function test (alt or ast) more than three times the upper limit of normal, or thrombocytopenia 3. severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment 4. pregnant or lactating females 5. known tape allergies 6. current treatment for a seizure disorder 7. cystic fibrosis 8. active infection 9. a known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: 10. inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian) 11. presence of a known adrenal disorder 12. if on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study 13. abuse of alcohol 14. dialysis for renal failure
investigating the effects of orienting skin grafts parallel to skin tension lines on quality of life in head and neck located basal cell carcinoma

Conditions: Basal Cell Cancer; Grafting

Summary: the goal of this observational study is to learn about the effect of orienting graft for treatment of skin cancer in patients who undergo skin cancer excision and grafting for their skin cancer. the main question to answer is does orienting the grafts parallel with skin tension lines have any effect on quality of life or cosmetic results? participants who already underwent or planned to undergo an excision and grafting procedure will answer a qaulity of life tool and cosmetic results will be evaluated by two seperate dermatologist.


Eligibility criteria:
inclusion criteria: * patients with nodular basal cell carcinomas with a tumor size equal or less than 12 millimeters * a history of surgical excision and grafting exclusion criteria: * immunosuppressed patients * recurrent tumors * patients with bcc's that arose from the previously irradiated area * gorlin's syndrome diagnosis * illiterate individuals * i̇mpaired cognitive functions

Keywords: basal cell carcinoma skin tension lines grafting cosmetic outcome quality of life